CDKN2A and dysplasia: In Bhatia et al. study, the sensitivity for OPMD detection based on MGMT and CDKN2A methylation was calculated for different OPMDs, including leukoplakia (41% and 45%), oral leukoplakia without dysplasia (55% and 18%), oral submucous fibrosis (31% and 46%), and oral lichen planus (25% and 0%), respectively [34].